People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Wugen, Inc. | — | Other Health Care | Series D+ | $245.2M | $870.3M | 2025 |
| Cue Biopharma, Inc. | — | Biotechnology | Series B | $57.4M | $429.1M | 2016 |
| Zyngenia, Inc. | — | Other | Series A | $18.0M | $151.3M | 2009 |
| Resolve Therapeutics LLC | — | Other Health Care | Series A | $8.9M | $117.7M | 2011 |
Peter Kiener at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Kiener on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Peter A. Kiener | 2 | 3 |
| Somu Subramaniam | 1 | 17 |
| Robert Garland | 1 | 7 |
| Drew Dennison | 1 | 7 |
| Niall O'Donnell | 1 | 7 |
| Bosun Hau | 1 | 6 |
| Matthew Cooper | 1 | 5 |
| Amy Wang | 1 | 5 |
| Cameron Gray | 1 | 4 |
| Kevin Li | 1 | 4 |
| Christopher Marlett | 1 | 3 |
| Barry Simon | 1 | 3 |
| Anthony DiGiandomenico | 1 | 3 |
| Bali Muralidhar | 1 | 3 |
| Gary Schuman | 1 | 2 |
| Robert F. Garland | 1 | 2 |
| John P McKearn | 1 | 2 |
| Keith Vendola | 1 | 2 |
| Kumar Srinivasan | 1 | 2 |
| Joseph Amprey | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.